Revivocell awarded Future Innovation Fund for the development of a novel COVID-19 screening platform

Revivocell is delighted to have been awarded Future Innovation Fund from the Liverpool City Region for the development of a novel screening tool for COVID-19 virus. 

With the current COVID-19 pandemic there remains great uncertainty about number of future infections and possible deaths. There is a need for more accurate and cost effective detection tools that can be widely used without highly specialised training and expensive equipment. The current established detection tools are expensive and require dedicated equipment, trained personnel and numerous reagents which are running low. 

Revivocell will be collaborating with Daresbury Proteins to develop the new COVID-19 testing platform, which is rapid, easy to use, lower cost and highly accurate.  

A successful outcome from this project would realistically and significantly meet societal needs that have emerged due to the COVID-19 pandemic. Long-term benefits include testing for specific effectiveness of the emerging vaccines ensuring longer-lasting protection from the virus. In addition, this work will have direct impact on the management of the pandemic locally and strengthen life science manufacturing in the region.